Signaling sphingolipids are biomarkers for atopic dermatitis prone to disseminated viral infections

Life-threatening viral diseases such as eczema herpeticum (EH) and eczema vaccinatum (EV) occur in <5% of individuals with atopic dermatitis (AD). The diagnosis of AD, however, excludes all individuals with AD from smallpox vaccination. We sought to identify circulatory and skin lipid biomarkers...

Full description

Saved in:
Bibliographic Details
Published inJournal of allergy and clinical immunology Vol. 150; no. 3; pp. 640 - 648
Main Authors Berdyshev, Evgeny, Goleva, Elena, Bronova, Irina, Bronoff, Anna Sofia, Streib, Joanne E., Vang, Kathryn A., Richers, Brittany N., Taylor, Patricia, Beck, Lisa, Villarreal, Miguel, Johnson, Keli, David, Gloria, Slifka, Mark K., Hanifin, Jon, Leung, Donald Y.M.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.09.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Life-threatening viral diseases such as eczema herpeticum (EH) and eczema vaccinatum (EV) occur in <5% of individuals with atopic dermatitis (AD). The diagnosis of AD, however, excludes all individuals with AD from smallpox vaccination. We sought to identify circulatory and skin lipid biomarkers associated with EH and EV. Stratum corneum and plasma samples from 15 subjects with AD and a history of EH, 13 age- and gender-matched subjects with AD and without EH history, and 13 healthy nonatopic (NA) controls were analyzed by liquid chromatography tandem mass spectrometry for sphingolipid content. Sphingosine-1-phosphate (S1P) and ceramide levels were validated in plasma samples from the Atopic Dermatitis Vaccinia Network/Atopic Dermatitis Research Network repository (12 NA, 12 AD, 23 EH) and plasma from 7 subjects with EV and 7 matched subjects with AD. S1P lyase was downregulated in human primary keratinocytes to evaluate its effect on herpes simplex virus 1 (HSV-1) replication in vitro. The stratum corneum of patients with EH demonstrated significantly higher levels of free sphingoid bases than those in patients who were NA, indicating enhanced sphingolipid turnover in keratinocytes (P < .05). Plasma from 2 independent cohorts of patients with EH had a significantly increased S1P/ceramide ratio in subjects with EH versus those with AD and or who were NA (P < .01). The S1P level in plasma from subjects with EV was twice the level in plasma from subjects with AD (mean = 1,533 vs 732 pmol/mL; P < .001). Downregulation of S1P lyase expression with silencing RNA led to an increased S1P level and doubled HSV-1 titer in keratinocytes. Our data point to long-term abnormalities in the S1P signaling system as a biomarker for previous disseminated viral diseases and a potential treatment target in recurring infections.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
E.B. developed mass spectrometric approaches for the analysis of tape strip samples for lipid components, performed sample processing and data analysis, supervised the entire workflow of sample mass spectrometric processing, reviewed data, and wrote the manuscript. I.B. performed sample processing and data analysis. A.S.B. performed skin tape strip sample processing and data analysis. E.G. coordinated the sample processing and interaction between research sites, performed experiments with keratinocytes, reviewed the data, and coauthored the manuscript. D.Y.M.L. conceptually designed and coauthored the protocol, reviewed data, and coauthored the manuscript. K.A.V. assisted with real time PCR assays and analysis. B.N.R. performed skin tape strip sample processing. J.E.S. oversaw interaction between study sites and provided logistical support. P.T. was involved in patient enrollment, clinical visits assessments and skin biopsy and STS sampling at NJH. L.B. oversaw ADRN plasma samples registry. M.K.S. and J.H. were involved in the enrollment and characterization of EV and AD patients at OHSU.
Author contributions
ISSN:0091-6749
1097-6825
1097-6825
DOI:10.1016/j.jaci.2022.02.027